Acute Myocardial Infarction (AMI), a new study from Decision Resources, Inc., forecasts that treatment of AMI will improve during the next ten years as a result of increased uptake of current therapies, the use of new combinations of existing therapies, and the development of novel drugs. As treatment outcomes improve, AMI drug sales will continue to flourish, reaching $1.2 billion in 2009. Key therapeutic developments analyzed in Acute Myocardial Infarction include the following:

  (Photo:  http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )    -- The most promising AMI therapy in development is the novel use of      glycoprotein (gp) IIb/IIIa antagonists in combination with      thrombolytics and percutaneous coronary intervention (PCI). Thought      leaders interviewed for this study believe that this approach promises      the advantages of improved patency in the infarcted artery and better      survival outcomes.   -- Alteplase (Genentech's Activase) is the current gold standard for      pharmacological thrombolysis in AMI. With the arrival of tenecteplase      (Genentech's TNKase, Metalyse), however, alteplase is expected to      tumble from first place. Tenecteplase is administered in a single IV      bolus, a feature that allows administration by emergency personnel,      enabling its effects to commence before the patient reaches the      hospital. Tenecteplase is rapidly gaining ground in the United States,      where it is soon expected to become the market leader.   -- Reteplase (Hoffmann-La Roche's Retavase) showed efficacy superior to      that of alteplase in trials, but failed to show improved survival      rates. Thus, despite its simplified dosing regimen, reteplase has      failed to supercede alteplase as the thrombolytic leader.  

Acute Myocardial Infarction offers invaluable market intelligence for pharmaceutical companies competing in the AMI market, and is a part of Cardium, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit Decision Resources at http://www.dresources.com/.

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or sama@dresources.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, 781-296-2553,
sama@dresources.com

Decision Resources Study Examines Next-Generation Antihistamines Looking to Capture Market Share for Allergic Rhinitis as Leading Second-Generation Antihistamines Near Patent Expiry

View Now